Feed ADMA
AD

ADMA Biologics ADMA NASDAQ · Healthcare · United States

$13.16 -1.35% -$0.18

Market cap
$2.96B
Enterprise value
$3.04B
P/E
16.2x
Forward P/E
14.7x
PEG
-
P/S
5.7x
P/FCF
22.3x
EV/EBITDA
12.0x
ROIC
28.2%
Gross margin
68.5%
Net margin
35.1%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
0.3x
Beta
0.77
Free float
98.1%

Sector

Healthcare

Industry

Biotechnology

CEO

Adam S. Grossman

Employees

644

Headquarters

Ramsey

Valuation

Is today's price reasonable?

  • What speaks for it: The share price is below the Bulios Fair Price.

Growth and estimates

Is it growing, and what comes next?

  • What speaks for it: Revenue grew by 49% a year over the last 3 years.
  • What to watch: Earnings per share swing sharply from year to year.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What speaks for it: Out of every 100 USD of revenue, 35 USD is left as net profit.
  • What speaks for it: It earns 28 USD a year on every 100 USD of invested capital.

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy